Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Amazon.com, Inc. (AMZN) -- Ignore unavailable to you. Want to Upgrade?

To: H James Morris who wrote (135675)	12/13/2001 5:35:25 PM
From: Victor Lazlo	Respond to of 164687

10866 Wilshire Blvd., Ste. 1270 Los Angeles, CA 90024 (Map) Phone: 310-470-4222 Fax: 310-470-7472 appdrugs.com Inject this! American Pharmaceutical Partners (APP) markets some 400 generic injectable drugs, focusing on the areas of oncology, antibiotics, and critical care (which includes blood thinners, anti-psychotics, and HCG, the human chorionic gonadotropin hormone). The company manufactures over 100 of its products, while it markets almost 300 through agreements with other generic drug firms. APP plans to license the North American rights to a generic version of paclitaxel (the active ingredient in Taxol, a top selling cancer drug marketed by Bristol-Myers Squibb) from American BioScience. Chairman and CEO Patrick Soon-Shiong (through his control of American BioScience) owns about 85% of APP prior to the IPO. Top Competitors Bristol-Myers Squibb \| Eli Lilly \| Watson Pharmaceuticals